Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Portuguese Heart Failure Observational Study – Madeira (PORTHOS-MADEIRA): Characteristics individuals with NT-proBNP elevation
Session:
SESSÃO DE POSTERS 46 - EPIDEMIOLOGIA PORTUGUESA NO FOCO
Speaker:
Gonçalo Bettencourt Abreu
Congress:
CPC 2025
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.2 Chronic Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Cartazes
FP Number:
---
Authors:
Gonçalo Bettencourt Abreu; Francisco Sousa; Débora Sá; Ricardo Rodrigues; João Adriano Sousa; M. Raquel Santos; Margarida Temtem; Maria João Oliveira; Eva Henriques; Marisa Sousa; Paula Gouveia; Graça Caires
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">Introduction: </span></span></strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">The Portuguese Heart Failure Observational Study - MADEIRA (PORTHOS - MADEIRA) is currently being carried out to assess the prevalence of heart failure (HF) in the Autonomous Region of Madeira (RAM). N-terminal pro-B-type natriuretic peptide (Nt-proBNP) is released mainly by stretch of the cardiomyocytes, and is an important marker in the diagnosis of HF. It also has prognostic value in patients with ventricular dysfunction.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">Objective: </span></span></strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">To assess the profile of patients with elevated NT-proBNP.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">Methods: </span></span></strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">We carried out an observational, cross-sectional, population-based study in the RAM. It was randomly selected a sample of the population aged at least 50 and living in the RAM. Individuals with NT-proBNP ≥ 125pg/mL and/or a reported history of HF progressed to stage 2, as did 5% of individuals who did not fulfil these criteria to serve as controls. We carried out a bivariate analysis using the chi-square test for categorical variables and the Student's t-test for continuous variables in order to assess the differences in the characteristics of phase 1 and phase 2 individuals, excluding those who were selected for the control group in the latter phase.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">Results: </span></span></strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">We obtained a sample of 1394 individuals, of whom 413 progressed to phase 2 (411 due to NT-proBNP >125pg/mL and 2 known HF). Comparing the two groups, we found statistically significant differences in age (p <0.0001), smoking (p=0.004), hypertension (p<0.0001), dyslipidaemia (p<0.0001), diabetes (p<0.0001), atrial fibrillation (p<0.0001), coronary artery disease (p<0.0001), peripheral artery disease (p=0.001), cerebrovascular disease (p<0.0001), New York Heart Association functional classification (p<0.0001) and level of education (p<0.0001).</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">Conclusion: </span></span></strong><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif">Individuals with NT-proBNP ≥ 125pg/mL or with a reported history of HF have more cardiovascular (CV) risk factors, CV history and a lower educational level.</span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site